Eli Lilly and Company  (LLY) Trade Now »     Rate LLY  -  Discuss LLY  -  Add to Watch List        

Stock Picks for Healthy Returns

A Backlog of Decisions is Building at the FDA

The accompanying table presents 70 FDA product approval decision dates along with the market caps and one year stock price change for the underlying companies. A note of caution for investors and traders is that the most common outcome from the FDA in the past year has been a delay in decisions due to understaffed conditions at the agency. However, several companies have pending decisions which are likely to occur either before year-end or early next year and will have a major impact on their stock prices.

Disco

LLY's projected P/E is 7.47
Industry (Drug Manufacturers - Major) average projected P/E 9.76
Implies a projected stock price of $42.07

LLY's PEG is 1.47
LLY's projected earnings growth rate is 5.08%
Industry (Drug Manufacturers - Major) average PEG is 2.24
Implies a projected stock price of $49.07

More analysis source, calculations, and other info:

http://www.freestockvalueranker.com/?method=peg_pe&symbol...

Analysis current as of October 19, 2008

FDA Calendar of Decision Dates: Some Likely Near-Term Movers

Some likely near-term movers on the FDA's decision date calendar for 70 different items (click to enlarge, left) include Cypress Bioscience ( CYPB ) + partner Forest Labs ( FRX ) with a pending decision on milnacipran in the treatment of fibromyalgia slated for the end of October in addition to results from a Phase 3 trial for the drug some time before year end.

Also, Discovery Labs ( DSCO ) is not listed on the calendar, but expects to file a complete response to a May 1st FDA approvab

ImClone Systems (IMCL) is set to sell itself for $6.1B or about $70 per share to the mystery big pharma bidder that Chairman Carl Icahn introduced as a defense against Bristol-Myers (BMY) original offer of $60, which was recently upped to $62 per share for the remaining 83% stake it does not already own. I have written about the saga on my blog since the end of July when Bristol-Myers made the original offer, but the Wall Street Journal s reporting the most likely bidders are Pfizer (PFE) or Eli Lilly (LLY).

Both of these big pharmas are in need of a pipeline and have the cash t

Eli Lilly Sinks After Hours on Effient Delay

Eli Lilly (LLY) and Daiichi Sankyo (Tokyo: 4568) announced on Friday evening that the FDA had not completed its regulatory review for its blood thinner drug, which would go by the brand name of Effient (prasugrel). The FDA previously delayed its decision by three months earlier this summer, but in this case no new deadline was set by the agency. Shares of Eli Lilly slid by about 4% after hours on less than 100,000 shares traded, closing near its 52-week low at $45.01 per share on Friday evening. However, the current sli

Full FDA Calendar of Decision Dates

The accompanying table presents a full FDA calendar of decision dates updated through today, which I will maintain at the bottom of my blog in place of the previous Global Carbon Trading Index. Click on the calendar image above or on my blog to view or download the PDF version of the FDA calendar, which I will also maintain at: www.geocities.com/mikehavrx/fdac.pdf .

Several key decisions are pending through the end of this month for the group of 14 big pharma companies I outlined yesterday, including Eli Lilly (L

Filed under: Pfizer (PFE), Newsletters, Johnson and Johnson (JNJ), Abbott Laboratories (ABT), Bristol-Myers Squibb (BMY), Merck and Co (MRK), Lilly (Eli) (LLY), Stocks to Buy

"You can invest for all the right reasons and still get the wrong result," notes long-standing turnaround stock expert George Putnam, referring to the poor performance of the pharmaceutical sector in recent years.

Here, in his industry-leading The Turnaround Letter, he offers a fascinating review of 10 leading drug stocks which he now believes offer a combination of growth potential at "pretty cheap" valuations. Here is